Last reviewed · How we verify

Beijing Shenogen Biomedical Co., Ltd — Portfolio Competitive Intelligence Brief

Beijing Shenogen Biomedical Co., Ltd pipeline: 0 marketed, 0 filed, 2 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Sorafenib Tosylate Tablets Sorafenib Tosylate Tablets phase 3 multi-kinase inhibitor RAF kinase, VEGFR, PDGFR Oncology
HUACHANSU PIAN HUACHANSU PIAN phase 3 Traditional Chinese medicine extract; natural product Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Technical University of Munich · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Beijing Shenogen Biomedical Co., Ltd:

Cite this brief

Drug Landscape (2026). Beijing Shenogen Biomedical Co., Ltd — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/beijing-shenogen-biomedical-co-ltd. Accessed 2026-05-16.

Related